

# GOPEN ACCESS

**Citation:** Salas-Briceno K, Zhao W, Ross SR (2024) Murine leukemia virus infection of non-dividing dendritic cells is dependent on nucleoporins. PLoS Pathog 20(1): e1011640. https://doi.org/10.1371/journal.ppat.1011640

Editor: Edward M. Campbell, Loyola University Chicago, UNITED STATES

Received: August 29, 2023

Accepted: January 2, 2024

Published: January 12, 2024

**Copyright:** © 2024 Salas-Briceno et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All raw data are deposited in a Mendeley file. https://data.mendeley. com/datasets/zmgp7dsj3m/1

**Funding:** This work was funded by grants from the NIH awarded to SRR: NIH/NIAID R01 AI174538 and NIH/NIAID R01AI085015. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

**RESEARCH ARTICLE** 

# Murine leukemia virus infection of non-dividing dendritic cells is dependent on nucleoporins

#### Karen Salas-Briceno, Wenming Zhao, Susan R. Rosso\*

Department of Microbiology and Immunology, University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States of America

\* srross@uic.edu

# Abstract

Retroviral reverse transcription starts within the capsid and uncoating and reverse transcription are mutually dependent. There is still debate regarding the timing and cellular location of HIV's uncoating and reverse transcription and whether it occurs solely in the cytoplasm, nucleus or both. HIV can infect non-dividing cells because there is active transport of the preintegration complex (PIC) across the nuclear membrane, but Murine Leukemia Virus (MLV) is thought to depend on cell division for replication and whether MLV uncoating and reverse transcription is solely cytoplasmic has not been studied. Here, we used NIH3T3 and primary mouse dendritic cells to determine where the different stages of reverse transcription occur and whether cell division is needed for nuclear entry. Our data strongly suggest that in both NIH3T3 cells and dendritic cells (DCs), the initial step of reverse transcription occurs in the cytoplasm. However, we detected MLV RNA/DNA hybrid intermediates in the nucleus of dividing NIH3T3 cells and non-dividing DCs, suggesting that reverse transcription can continue after nuclear entry. We also confirmed that the MLV PIC requires cell division to enter the nucleus of NIH3T3 cells. In contrast, we show that MLV can infect non-dividing primary DCs, although integration of MLV DNA in DCs still required the viral p12 protein. Knockdown of several nuclear pore proteins dramatically reduced the appearance of integrated MLV DNA in DCs but not NIH3T3 cells. Additionally, MLV capsid associated with the nuclear pore proteins NUP358 and NUP62 during infection. These findings suggest that simple retroviruses, like the complex retrovirus HIV, gain nuclear entry by traversing the nuclear pore complex in non-mitotic cells.

# Author summary

Retrovirus replication requires nuclear entry of reverse-transcribed double-stranded viral DNA and integration into the host cell chromosomes. It is widely believed that unlike lentiviruses, simple retroviruses like MLV require nuclear membrane breakdown during cell division to achieve nuclear entry of viral reverse transcription products to complete their replication. We show here that while this is true for rapidly dividing tissue culture cells, in quiescent primary cells like dendritic cells, the likely initial targets of *in vivo* MLV infection, the virus establishes infection without cell division. MLV accomplishes this because the viral capsid protein interacts with proteins in the nuclear membrane in DCs. In contrast, while this interaction occurs in dividing tissue culture cells, it is not sufficient for nuclear entry of viral DNA. These studies show that the requirements for retrovirus infection depend on the cell type and moreover, partially overturn the dogma that simple retroviruses need cell division to complete replication.

### Introduction

Retroviruses enter cells when the viral and host membranes fuse. Retroviruses replicate by reverse transcribing viral RNA into DNA using the virus-encoded reverse transcriptase (RT) [1]. Reverse transcription initiates within the capsid and capsid dissociation and reverse transcription are mutually dependent; a rigid capsid prevents reverse transcription from proceeding and the generation of DNA, which is more rigid than RNA, promotes capsid dissociation [2]. After reverse transcription and nuclear entry of the preintegration complex (PIC), which contains reverse-transcribed viral DNA in complex with host and viral proteins, the double-stranded DNA provirus integrates into the host genome via interaction of the viral integrase (IN) and host proteins like lens epithelium-derived growth factor (LEDGF; HIV) and bromodomain and extra terminal family proteins (BETs; MLV) [3–5].

Lentiviruse PICs enter the nucleus of quiescent cells through interaction of viral capsid/ nucleocapsid proteins with the nuclear pore complex (NPC) [6]. Retroviruses like MLV and mouse mammary tumor virus (MMTV) require cell division and nuclear membrane breakdown for PIC entry because they are thought to lack viral proteins that interact with the NPC [6–10]. MLV, like HIV, dissociates its capsid to achieve integration [6]. The MLV p12 protein, encoded by the *gag* gene, tethers the PIC to chromosomes, allowing it to access chromosomes during mitosis [11]. Both MLV and MMTV infect non-dividing dendritic cells (DCs) *in vivo* [12–14]; how nuclear entry occurs in these cells is not known.

Recently, there has been debate as to where in the cell HIV reverse transcription occurs. Using HIV pseudoviruses bearing VSV G protein and tissue culture cells, several groups have shown that CA-containing reverse transcription complexes (RTC) enter the nucleus and that viral DNA synthesis is nuclear [15–18]. Capsid clearly contributes to HIV reverse transcription and integration; it has been demonstrated in a cell-free system that small patches of HIV-1 capsid loss are needed to accommodate the growing RTC and initiate integration [19]. Unlike the bullet shape of the HIV capsid, which is thought to facilitate nuclear pore entry, little is known about where reverse transcription occurs for other retroviruses including MLV, whose capsids are spheroid or polyhedral [9].

Another unresolved issue for all retroviruses is the timing and location of host restriction during infection, particularly in natural targets of infection (e.g., lymphocytes, macrophages, dendritic cells) and how these factors coordinate with reverse transcription. Host anti-viral factors like apolipoprotein B mRNA editing enzyme catalytic subunit 3 (APOBEC3) proteins, which are packaged into retroviral virions, deaminate cytidine residues in the single-stranded DNA (ssDNA) generated by reverse transcription, thereby resulting in uracilated DNA, but whether this occurs in the nucleus, cytoplasm or both is not known. We recently showed that the nuclear base excision repair enzyme that removes uracil from ssDNA, uracil DNA glycosylase (UNG) works in the nucleus but not the cytoplasm to remove U residues from unintegrated MLV DNA deaminated by APOBEC3G, suggesting that at least some reverse

transcription occurs in this compartment [20]. However, many sensors that detect HIV and MLV reverse transcripts, including cGAS, TREX1 and STING, are largely cytoplasmic and we and others have shown that sensing by these factors is sensitive to capsid stability [21–25]. Indeed, MLV encodes a protein called glycosylated Gag (glycoGag) protein that enhances capsid stability and prevents APOBEC3 and nucleic acid sensors from accessing the RTC [21,22]. Similar results have been demonstrated for HIV [23–26]. For example, the HIV-2 capsid is more labile than the HIV-1 capsid and is more susceptible to nucleic acid sensors [23].

Here we show that MLV requires cell division to efficiently enter the nucleus of NIH3T3 cells, although low levels of infection could be detected in quiescent cells. We also found that MLV RNA/DNA hybrid intermediates could be detected in the nucleus as well as the cytoplasm of dividing cells, suggesting that reverse transcription can occur after nuclear entry if reverse transcription is not complete prior to reformation of the nuclear envelope after cell division. In contrast to NIH3T3 cells, we found that MLV readily infected non-dividing primary dendritic cells and that early reverse transcripts could be equally detected in the nucleus and cytoplasm. Moreover, knockdown of several nucleoporins (NUPS) implicated in HIV trafficking across the nuclear envelope dramatically reduced the appearance of integrated MLV DNA in DCs but not NIH3T3 cells. These data suggest that MLV's requirement for cell division is cell type-dependent and that in natural targets of infection, MLV PICs traffic across the nuclear membrane and efficiently establish infection.

#### Results

#### Incoming MLV capsid is found in the nucleus

Recent studies have demonstrated that HIV capsid can be detected in the nucleus at early times post-infection (reviewed in [27]). We first determined if MLV capsid (CA) could be found in the nucleus shortly after infection. NIH3T3 cells were infected with Moloney MLV and at 2- and 4-hours post-infection (hpi), the cells were fractionated and subjected to western blot analysis using anti-MLV CA antibodies. As positive controls, NIH3T3 cells persistently infected with MLV were also tested. At 2 and 4 hpi, CA was readily detected in the nuclear fractions (Fig 1A). Nuclear CA was also detected in persistently infected cells. Thus, like HIV, MLV capsid can be detected in the nucleus early after infection.

# MLV reverse transcription intermediates are found in the nuclei of NIH3T3 cells

Many labs have studied MLV replication in growth-arrested, non-dividing tissue culture cells and shown that cell division is required for infection [6–8]. We also looked at virus spread in serum-starved and the reverse transcription inhibitor zidovudine/azidothymidine (AZT)treated cells, by measuring the level of MLV envelope sequences in genomic DNA at different times post-infection (Fig 1B). As has been shown previously, the level of MLV increased by 48 hpi in untreated cells, while in the serum-starved there was no spread at 48 and 72 hpi, compared to 24 hpi (Fig 1C). AZT inhibited all virus spread.

We also determined that induction of quiescence by serum starvation blocked integration at 24 hpi. NIH3T3 cells were grown in 0.2% or 10% fetal calf sera for 48 hr and then infected with MLV. Integration was measured using a *Line-1/gag* nested PCR, similar to the *Alu/gag* approach used to detect HIV integration (Fig 1B) [20,28]. Treatment of cells infected with MLV with AZT or the integrase inhibitor raltegravir decreased integration by –13 and 5-fold, respectively. We found that serum starvation reduced but did not completely eliminate MLV integration (3-fold reduction; Fig 1D). In high serum, over 80% of cells were infected, while



**Fig 1. Efficient replication of MLV in NIH3T3 cells requires cells division.** A) MLV (MOI = 1) was incubated on ice for 1 hr with NIH3T3 cells and warmed to 37 °C for the indicated times. Western blots on fractionated extracts were performed with the indicated antibodies. NIH3T3 cells persistently infected with virus were used as positive controls. LAMIN B1 and GAPDH served as controls for nuclear and cytoplasmic fractions, respectively. This experiment was repeated 3 times with similar results. B) Map of the MLV genome and the primers used to detect integrated proviruses (round 1 PCR L1-gag/gag and round 2 nested PCR LTR primers) and virus infection levels (SU). C) NIH3T3 cells were grown in 0.2% or 10% serum, infected with MLV (MOI = 1) and infection levels were measured at the indicated times. AZT treatment was used to block virus spread. D) Integrated MLV was determined in dividing, serum-starved and AZT- or raltegravir-treated cells. Shown to the right is the MTT assay, demonstrating that serum starvation decreased cell division. All experiments were performed 3 times. Shown is the average ± SD. Significance was determined by 2-way ANOVA, using Tukey's multiple comparisons test (MLV in C and integrated MLV in D) or unpaired T test (MTT). \**P* ≤ 0.03; \*\**P* ≥ 0.000; \*\*\* *P* ≤ 0.0001.

<30% of cells were infected in low serum (S1A Fig). However, it is possible that the low-level integration detected in serum-starved cells resulted from incomplete inhibition of cell division, since the reduction in cell division was incomplete (75–85%) (Figs 1D and S2). To improve the inhibition of cell division, we tried aphidicolin treatment to arrest cells, but also saw that a small percentage of cells continued to replicate (S2 Fig). In addition, aphidicolin treatment was more toxic than serum starvation (S2 Fig).

We next determined where reverse transcription intermediates were found in different compartments of dividing and quiescent cells. Untreated and serum starved NIH3T3 cells were infected with MLV and at 4 hpi, nuclear and cytoplasmic fractions were immunoprecipitated with S9.6 antibody, which recognizes RNA/DNA hybrids. The nucleic acid was eluted from the immunoprecipitates and subjected to reverse-transcribed PCR, using primers that

recognize early reverse transcripts ( $P_{tRNA}$  and  $P_R$  and  $P_R$  and  $P_{U5}$ ; Fig 2A). Western blots demonstrated that the nuclear and cytoplasmic fractionation was successful (Fig 2B). In dividing cells, low amounts of the  $P_{tRNA}/P_R$  product were detected in the nucleus, at about 10-fold lower levels than in the cytoplasm (Fig 2C). However, strong-stop DNA was detected at almost equal amounts in nuclear and cytoplasmic fractions. In contrast, in serum-starved cells both the  $P_{tRNA}/P_R$  and strong-stop DNA were greatly reduced in the nucleus.

To ensure that the immunoprecipitated products were RNA/DNA hybrids, we treated the fractions with DNaseI, RNaseH and RNaseA. Only RNaseH and DNaseI abolished the PCR products, confirming that the products were early reverse transcripts (Figs 2D and S1C). Taken together, these data show that cell replication is needed for efficient trafficking of the PIC into the nucleus of NIH3T3 cells but suggest that partially reverse-transcribed replication products can complete replication in the nucleus after cell division finishes.

We also used proximity ligation assays (PLA) to examine the co-localization of reverse transcripts and MLV proteins, using the S9.6 antibody and anti-MLV antibodies. DNA/RNA hybrids co-localized with MLV nucleocapsid (NC) at the nuclear membrane, and cytoplasm of infected but not uninfected cells; low levels of co-localization were also seen in the nucleus (Fig 2E). Similar results were seen with the anti-RT antibodies, although there were also PLA positive signals in the cytoplasm of uninfected cells (Figs 2F and S3). No PLA signal was seen when anti-RT or S9.6 antibodies were used alone with infected cells (S4 Fig). Previous studies have suggested that NIH3T3 cells express endogenous MLVs, at least at the RNA level, which may be the source of this signal [29–31].

These data show that reverse transcription can occur in the nuclei of non-dividing NIH3T3 cells, but that it is inefficient and confirm previous findings that MLV replication in tissue culture cells requires cell division.

#### Non-dividing DCs are efficiently infected with MLV

We previously showed that DCs can be infected with both MMTV and MLV *in vivo* and *in vitro* [12,14]. Once differentiated, DCs are non-replicating. We next tested whether DCs isolated from bone marrow (BMDC) could be infected with MLV. Because we showed previously that mouse APOBEC3 can reduce early reverse transcription of incoming virus, we used BMDCs isolated from APOBEC3 knockout mice for these experiments to increase sensitivity; NIH3T3 cells do not express APOBEC3 [32–34]. We first confirmed that >98% of DCs analyzed at 10–11 days of differentiation ex vivo were quiescent (Fig 3A). These cells were then infected with MLV and at 24 hpi, genomic DNA was analyzed for integrated MLV. Integrated DNA was easily detected, and the levels were reduced by treatment with AZT and raltegravir (Fig 3B). Approximately 15% of untreated DCs in the culture had integrated MLV DNA (S1B Fig). Moreover, infected DCs shed infectious virus, albeit at very low levels (S5A and S5B Fig).

Next, to determine where early reverse transcription was occurring, we infected DCs and at 4 hpi, carried out fractionation followed by pulldown with S9.6 antibody and analysis of the bound nucleic acid. Unlike what we saw with NIH3T3 cells, approximately equal levels of both the P<sub>tRNA</sub>/P<sub>R</sub> and P<sub>tRNA</sub>/P<sub>U5</sub> RT-PCR products were found in the nucleus and cytoplasm (Fig 3C). This suggested that MLV reverse transcription occurred in both compartments of infected DCs. We also found, using PLA, that RNA/DNA hybrids co-localized with MLV NC at the nuclear membrane and the cytoplasm and nucleus of DCs at almost equal levels (Fig 3D). Similar results were seen with co-localized RT (Fig 3E). As we saw with NIH3T3 cells, a small PLA signal with anti-RT and S9.6 antibodies could be detected in uninfected cells.



**Fig 2. Early reverse transcripts (ERTs) are both nuclear and cytoplasmic.** A) Map of the primers used to detect ERTs. B) Western blot showing cell fractionation. LAMIN B1 was used to identify nuclear and TUBULIN cytoplasmic fractions. C) Nuclear, cytoplasmic and total extracts from dividing NIH3T3 cells infected with MLV (MOI = 1) were immunoprecipitated with antibody S9.6, the nucleic acid was released from the immunoprecipitates and subjected to qPCR with primers that detect the 1st step of reverse transcription ( $P_{tRNA}/P_R$ ) and strong stop DNA ( $P_R/P_{U5}$ ). Shown is the average of 3 experiments ± SD. D) The immunoprecipitates from (C) were treated with the indicated enzymes prior to qPCR. Shown is the average of 3 experiments ± SD. E) and F) PLA was performed using antibodies to MLV NC (p10) (E) or RT (F) and S9.6. Shown below the photographs is quantification of the appearance of the PLA+ spots in different cellular locations (25 fields; 210–270 cells). Shown is the average number for each location per field ± SD. Significance was determined by 1-way ANOVA. \* $P \le 0.04$ ; \*\* $P \le 0.005$ ; \*\*\* $P \le 0.003$ ; \*\*\*\* $P \le 0.0001$ .

### MLV p12 is required for BMDC infection

The MLV *gag* gene encodes a protein, p12, which is required for anchoring of viral dsDNA to the chromosomes, thereby facilitating integration in dividing cells [11,35,36]. To determine if p12 was also required for integration in non-dividing BMDCs, we infected them with mutant p12-M63-PM15, in which the C-terminal residues (70RREPP74) were replaced with alanines

![](_page_6_Figure_2.jpeg)

Fig 3. Primary DCs are readily infected with MLV. A) Representative FACS plot demonstrating that primary DCs are non-dividing. B) BMDCs were infected with MLV (MOI = 1) and integrated proviral DNA was measured. AZT and raltegravir treatment were used as controls to inhibit infection. Shown is the average of 3 independent experiments  $\pm$  SD. C) Nuclear, cytoplasmic and total extracts from BMDCs were immunoprecipitated with antibody S9.6 and subjected to qPCR with primer pairs P<sub>tRNA</sub>/P<sub>R</sub> and P<sub>R</sub>/P<sub>U5</sub>. Experiments were performed a minimum of 3 times. Shown is the average  $\pm$  SD. Significance was determined by 1-way ANOVA. ns, not significant. Shown below the graphs is a representative western blot showing the fractionation purity. LAMIN B1 was used to detect nuclear and TUBULIN to detect cytoplasmic fractions. D) and E) PLA was performed using antibodies to MLV NC (p10) (D) or RT (E) and S9.6. Shown below the photographs is quantification of the appearance of the PLA+ spots in different cellular locations (25 fields; 480–570 cells). Shown is the average number for each condition per field  $\pm$  SD. Significance was ANOVA. \*P $\leq$  0.04; \*\*P $\leq$  0.002; \*\*\*P $\leq$  0.0004; \*\*\*\*P $\leq$  0.0001.

(70AAAAA74); this mutation abrogates chromatin binding of the PIC in dividing cells [36]. For comparison, we used pNCA, the cloned parental virus from which p12-M63-PM15 was constructed. No integrated DNA could be detected in p12-M63-PM15-infected cells at 24 hpi, while pNCA infected BMDCs to a similar extent as wild type MLV (Fig 4A). The

![](_page_7_Figure_2.jpeg)

**Fig 4. MLV p12 is needed for integration in BMDCs.** A) Integrated MLV was determined in MLV wildtype (MLV and pNCA MLV)- and p12 mutant MLV (PM15)infected cells. All experiments were performed 3 times. Shown is the average  $\pm$  SD. Significance was determined by unpaired T test. \**P* $\leq$  0.0167. B) Nuclear DNA was amplified with primers that detect 2-LTR circles. Experiments were performed 3 times. Significance was determined by 1-way ANOVA. \*\**P* $\leq$  0.01. C) Nuclear, cytoplasmic and total extracts from BMDCs infected with the indicated virus were immunoprecipitated with antibody S9.6, the nucleic acid was released from the immunoprecipitates and subjected to qPCR with primers that detect the 1st step of reverse transcription (P<sub>tRNA</sub>/P<sub>R</sub>) and strong stop DNA (P<sub>R</sub>/P<sub>U5</sub>). Shown is the average of 3 experiments  $\pm$  SD. No significant difference was seen between any of the groups using 1-way ANOVA.

p12-M63-PM15 PIC did enter the nucleus, however, because 2-LTR circles, the nuclear byproduct of unintegrated reverse-transcribed DNA, were detected at about 2-3-fold higher levels than with MLV or pNCA MLV, as expected for viral DNA that is unable to integrate (Fig 4B). This level of 2-LTR circles was similar to what was seen when the cells were treated with the integrase inhibitor raltegravir (S6 Fig). Moreover, RNA/DNA early reverse transcription products were equally detected in the cytoplasm and nucleus in MLV-, pNCA MLV- and p12-M63-PM15-infected BMDCs at 4 hpi (Fig 4C). Thus, like dividing cells, MLV p12 is required for integration of viral DNA into the chromosomes of quiescent DCs.

#### MLV infection of DCs relies on nucleoporins

It is well-established that the HIV PIC relies on the nuclear pore for entry into the nucleus of quiescent cells. Several nucleoporins have been implicated in this transport, including NUP358, NUP62, NUP88, NUP153 and NUP214 [37,38]. To determine if any of these NUPs were required for MLV nuclear entry, we used siRNA knockdown in NIH3T3 cells (Fig 5A) and BMDCs (Fig 5B) to deplete their expression. As controls, AZT and raltegravir were used to block infection. In NIH3T3 cells, siRNA knockdown of these 5 nucleoporins had no effect on MLV infection at 24 hpi, as integrated provirus levels were equal to cells treated with the control siRNA (Fig 5A). In contrast, knockdown of all 5 nucleoporins dramatically reduced infection in BMDCs, to similar levels seen with AZT and raltegravir treatment (Fig 5B). Knockdown efficiency was similar in both cell types, and cell viability was not affected, as determined by MTT assays (Fig 5A and 5B). By examining the fluorescence intensity in cells immunostained for each of the nucleoporins, we also found that knockdown of most appeared to reduce the levels of the others, with the exception of NUP358 and NUP88 (Figs 5C and S6). However, NUP358 and NUP88 knockdown was less efficient at the protein level than the other NUPS, so this might account for the lack of effect on expression of other NUPs (Fig 5C and S6).

We used PLA to determine whether MLV capsid co-localized with any of the NUPs. We were able test 2 nucleoporins, NUP358, which is located on the cytoplasmic side of the nuclear pore and NUP62, found within the channel, with anti-capsid antibody; antibodies to the other nucleoporins either did not work well for PLA or were from species not compatible with the anti-MLV CA antibody. To first examine interaction, we used a NIH3T3 cell line stably transfected with a CMV-driven gag/pol construct [13]. Many cells showed multiple co-localization spots with both nucleoporins (Fig 6A). The PLA spots detected with NUP358 and NUP62 and CA antibodies localized to the cytoplasm, nuclear membrane and nucleus (Fig 6A).

We next examined the co-localization of capsid and NUPs in MLV-infected NIH3T3 cells and BMDCs at 4 hpi. In both cases, co-localization of capsid was detected with both NUP358 and NUP62 (Fig 6B and 6C). Interestingly, while NUP62/capsid was found inside the nucleus in infected BMDCs, in infected NIH3T3 cells the spots were mainly seen in the cytoplasm. This supports the preceding evidence that nuclear entry of MLV PICs largely requires cell division in NIH3T3 cells but not DCs.

#### Discussion

Historically, it was thought that retroviral reverse transcription occurred entirely in the cytoplasm. However, recent studies have demonstrated HIV reverse transcription happens at least partially in the nucleus, although whether it initiates in this location is still under debate [15,18,27,39,40]. Here we showed that MLV reverse transcription occurs in the cytoplasm and nucleus of both dividing and non-dividing cells. In dividing cells, like NIH3T3 cells, we found that most reverse transcription is cytoplasmic, but that it can be completed in the nucleus. Since blocking NIH3T3 cell division greatly decreased the appearance of RTCs in the nucleus, nuclear reverse transcription likely occurs when the RTC ends up in the nucleus post-cell division. These results also explain our previous findings in 293T cells, suggesting that RNA/DNA intermediate products of reverse transcription were nuclear; we showed that although APOBEC3G largely deaminates cytoplasmic MLV reverse transcripts, the nuclear enzyme UNG, which preferentially removes uracils found in ssDNA, acts on unintegrated nuclear viral DNA [20].

![](_page_9_Figure_2.jpeg)

**Fig 5. Depletion of NUP proteins decreases MLV infection of DCs but not NIH3T3 cells.** A) siRNA-mediated knockdown of the indicated NUPs in NIH3T3 cells. AZT and raltegravir treatment serve as controls. Knockdown efficacy is shown in the middle panel and effects on cell viability in the bottom panel. B) The same experiment was performed in BMDCs. All experiments were performed a minimum of 3 times. Shown is the average  $\pm$  SD. Significance was determined by 1-way ANOVA. \* $P \le 0.03$ ; \*\*\* $P \le 0.0009$ . C) The intensity of immunostaining for the indicated proteins after NUP knockdown was quantified. One hundred to 160 cells were analyzed for each knockdown condition. Representative images are shown in S7 Fig.

Even in serum starved NIH3T3 cells, there were low levels of RTCs found in the nucleus and integration and infection was reduced but not completely eliminated. Because we were unable to complete arrest cell division, either by serum starvation or aphidicolin treatment, we cannot rule out that this low-level infection is due to a small percentage of dividing cells. We also found that serum starved NIH3T3 cells had lower overall levels of reverse transcription even in the cytoplasmic fraction, which may be due to the diminution of other host factors needed for MLV entry, uncoating or reverse transcription (Fig 2C).

Many studies have shown that gammaretroviruses like MLV require cell division for viral replication, although these were performed in replication competent tissue culture cells and largely used virus spread as the readout for infection [6–8]. Here we show that in contrast to NIH3T3 cells, MLV PICs traffic across the nuclear membrane and efficiently infect non-dividing primary DCs. Whereas in NIH3T3 cells the appearance of RNA/DNA hybrids in the nucleus was greatly reduced, in DCs equal levels were seen in the nucleus and cytoplasm. Similarly, NC in particular was found at higher levels in association with RNA/DNA hybrids in the

![](_page_10_Figure_2.jpeg)

![](_page_10_Figure_3.jpeg)

nuclei of DCs compared to NIH3T3 cells. RT-RNA/DNA hybrid association also was lower in the nuclei and cytoplasm of NIH3T3 cells compared to DCs, although the difference was less pronounced than with NC. This may be because the nucleocapsid is more dissociated from PICs found in NIH3T3 nuclei than in DCs.

It is known that the nuclear pore complex mediates nucleo-cytoplasmic transport of macromolecules and is required for the trafficking of viral PICs and as a result, replication of HIV in quiescent cells (reviewed in [27,37]). In support of the trafficking of MLV RTCs/PICs in quiescent DCs compared to NIH3T3 cells, knockdown of various nucleoporins decreased MLV integration in the former but not the latter cell types. In addition, we were able to detect MLV capsid in the nucleus as early as 2 hpi, suggesting that some CA remains associated with the RTC following its translocation into the nucleus. Thus, like HIV, MLV capsid may be uncoated in two stages. The first stage is the loss of integrity of the intact core. This event likely occurs in the cytoplasm but does not remove all the CA from the HIV RTC prior to nuclear import [41]. Our results also indicate that MLV CA interacts with one or more of the same nucleoporins as HIV. In knockdown experiments, we were unable to directly assess which nucleoporin was critical, as knockdown of each nucleoporin altered the protein levels of the others. In the most dramatic case, *Nup62* knockdown decreased the expression of all other tested nucleoporins. We also observed that even though *NUP358* knockdown was not complete, it affected the MLV integration levels, indicating that even small disturbances in the nuclear pore alter the efficiency of MLV PIC nuclear entry. While knockdown of NUPs may have secondary effects that alter PIC nuclear entry, we did not see effects on either NIH3T3 or DC viability and NUP knockdown did not alter integration in NIH3T3 cells, suggesting that the requirement for nuclear trafficking in DCs is the direct result of the knockdown.

Finally, using PLA assays we showed that in both NIH3T3 cells and DCs, MLV capsid interacts with NUP358 and NUP62 (Fig 6C). This suggests that the block to nuclear entry in NIH3T3 cells is not due to lack of NUP protein interaction, but must be due to other factors, such as the architecture of the nuclear pore or a lack of unknown host proteins that allow MLV PIC to traffic across the nuclear membrane in these cells. NUP358 is found at the cytoplasmic side of the nuclear pore, while NUP62 is found in the channel [42]. We found that NUP358/CA interaction occurred equally in the cytoplasm and nucleus in both cell types, while NUP62/CA occurred in the nucleus and at the nuclear membrane in DCs but not NIH3T3s, where it was mostly seen in the cytoplasm. Whether this cytoplasmic interaction is the result of MLV causing NUP mislocalization is not clear. However, several other viruses, including HIV, have been shown to cause redistribution of NUPs to the cytoplasm (reviewed in [43]). Additional studies are also necessary to determine if MLV CA physically binds to multiple nucleoporins, and if MLV interaction with nucleoporins affects nucleocytoplasmic trafficking, or also affects MLV's access to the host chromatin and chromosomal site selection for integration. However, it is clear that even in nondividing DCs, the MLV p12 protein is still required for integration of viral DNA into the chromosomes.

Thus, our work shows that the gammaretrovirus MLV can infect non-dividing cells like DCs, thought to be the initial *in vivo* targets of MLV [12,13,44]. Interestingly, previous studies have suggested that gammaretroviruses can infect other quiescent cell types, such as neurons [45]. Our studies also suggest that reverse transcription and partial uncoating of MLV virions occur in the cytoplasm. This supports the observation that APOBEC3G deaminates cytoplasmic reverse transcripts and that cytoplasmic nucleic acid sensors respond to MLV RNA/ DNA hybrids and reverse transcribed DNA [13,20,22,46]. This action by anti-viral cytoplasmic proteins is important for host defense, particularly in sentinel cells of the immune system like DCs. Perhaps the relatively low innate immune response to retroviruses compared to other RNA viruses is because of the rapid movement of RTCs to the nucleus in sentinel cells, thereby avoiding cytoplasmic detection.

#### Methods

#### Cell cultures

NIH3T3 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FBS, 2mM L-glutamine (Gibco), 100 U/ml penicillin (Gibco), and 100 µg/ml streptomycin (Gibco). Cell cultures were maintained at 37 °C with 5% CO2. For the BMDCs cultures, bone marrow from APOBEC3 knockout mice was harvested from the hind limbs of mice, cultured in RPMI supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ ml streptomycin, and 50 µM  $\beta$ -mercaptoethanol and differentiated with 20 ng/ml murine granulocyte-macrophage colony-stimulating factor (GM-CSF) (Peprotech, 315–03). BMDCs were stained for CD11c (Biolegend PE anti-mouse CD11c 117307) and analyzed by flow cytometry (LSR-Fortessa flow cytometer; BD Biosciences). DC cell populations resulted in cultures that were >80% pure (S8 Fig).

#### Cell cycle analysis by flow cytometry

NIH3T3 cells and BMDCs were incubated in Fc block (BD Biosciences) in 2% FBS in PBS and fixed and permeabilized with BD Cytofix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences). Then, cells were stained with 7-AAD Viability staining solution (BioLegend), Zombie Aqua Dye (BioLegend) and the antibody Alexa Fluor 700 anti-mouse Ki-67. Analysis was done in the LSR-Fortessa flow cytometer (BD Biosciences) using FlowJo v10 software (Tree Star, Inc.).

#### Virus isolation

Moloney MLV was isolated from the supernatants of stably infected NIH 3T3 cells (cells in which infection is allowed to spread to 100% of the culture and maintained in this state thereafter). pNCA MLV and p12-M63-PM15 plasmids were a gift from Monica Roth [36]. The pNCA MLV and p12-M63-PM15 plasmids were transfected into 293T cells using Lipofectamine 3000 (Invitrogen). The media of the transfected cells were harvested at 48 h post-transfection. Supernatants from NIH3T3 and 293T cells containing MLV were passed through a 0.45-mm filter, treated with 20 U/ml DNase I (Sigma) (NIH3T3 cells) or salt active nuclease (SERVA) (transfected 293T cells) at 37°C for 30 min, and centrifuged through a 25% sucrose cushion. After resuspension, titers of MLV and pNCA MLV were determined on NIH 3T3 cells. All viruses, including the PM15 mutant, were subjected to reverse transcriptase quantitative PCR (RT-qPCR) with primers located in the env gene and the number of viruses was estimated from the amount of virus-specific RNA, using standard curve analysis (Table 1). For PM15, one genome equivalent was used to infect cells. Equal amounts of virus, normalized by RNA levels, were also analyzed by Western blots (S9 Fig).

#### Virus infection

MLV levels were determined by infectious center (IC) assays using a focal immunofluorescence assay, as previously described [12]. Briefly, NIH3T3 cells were infected with 10-fold serial dilutions of virus. At 4 dpi, the plates were stained a monoclonal antibody (538) that recognizes the Env protein. After staining with fluorescein-conjugated secondary antibody, the colonies of green cells were quantified by automated counting using a Keyence fluorescence microscope. Viral titers (ICs) were calculated from the numbers of fluorescent colonies corrected for the dilution factors of the viral stocks in each plate. All infections were done at a MOI of 1. In some experiments, cells were treated with 100 nM raltegravir for 2 h or 5  $\mu$ M AZT for 1 hr prior to infection and then infected with MLV virus in the presence of drug.

#### Western blot analysis

For fractionation assays, NIH-3T3 cells were collected in ice-cold PBS, and fractionated into nuclear, cytoplasmic, and whole cell extracts by the Rapid, Efficient, and Practical (REAP) method (47). Cellular and viral proteins were detected by Western blots. Polyclonal goat anti-MLV antibody (NCI Repository) (34), anti-GAPDH (D16H11, Cell Signaling Technology/CST), anti- $\alpha$ -tubulin (T6074, Sigma-Aldrich), anti-lamin B1 (D4Q4Z, CST), horseradish per-oxidase (HRP)-conjugated anti-rabbit (7074, CST), and (HRP)-conjugated anti-goat (A8919, Sigma-Aldrich) were used for detection, using Pierce ECL Western blotting substrate (Thermo Fisher Scientific, 32209).

Gene	Primer sequence (5'-3')
NUP358	GCCCCGAGAGAAGTCAATGA / GTAGAAATGTATTTTTTAGCAAGATCA
NUP62	GAGTGAAGGCGCGAAACCTC / GCGGTCCCAAATGTAAAGCC
NUP88	CCATTACTCTCAGTGCCTACC / AGCCTTCAAGTTATGTTCATTCC
NUP153	GGGAGTGTCCAGTCTGCTGT / TCCCTCGGGCTTTTTAAACT
NUP214	TCTCCCAGAGTGCCAGGTAA / GCGGAGCTGCCTTCATCTAA
MLV SU	CCTACTACGAAGGGGTTG / CACATGGTACCTGTAGGGGC
2-LTR	ATCCGACTTGTGGTCTCGCTG / GAGTGAGGGGTTGTGGGGCTCT
GAPDH	CCCCTTCATTGACCTCAACTACA / CGCTCCTGGAGGATGGTGAT
LINE 1/Gag	CCTACTGAACATCACTTGGGG /TTCCGGGGGTTTCTCGTTTAT
LTR	CCTCCGATTGACTGAGTCGCCCC / ATGAAAGACCCCCGCTGACGG
$\overline{P_R/P_{U5}}$	CCTCCGATTGACTGAGTCGCCCC / ATGAAAGACCCCCGCTGACGG
P <sub>tRNA</sub> /P <sub>R</sub>	GCTCTCCAGGGCCCAAGTT / CCTCCGATTGACTGAGTCGCCCC

Table 1. RT-qPCR primers used to evaluate cell and viral nucleic acid levels.

#### Real-time qPCR

RT-qPCRs were performed with MLV SU or 2-LTR primers (Table 1) using a Power SYBR green PCR kit (Promega) and the QuantStudio 5 real-time PCR system (Applied Biosystems), as previously reported [20]. DNA quantifications were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The amplification conditions were  $50^{\circ}$ C for 2 min,  $95^{\circ}$ C for 10 min, 40 cycles of  $95^{\circ}$ C for 15 s, and  $60^{\circ}$ C for 1 min. The efficiency of amplification was determined for each primer pair by generating a standard curve with 10-fold serial dilutions of a known concentration of DNA. For each primer pair, a no-template control was included, and each sample was run in triplicate. Levels of integrated MLV were determined by LINE1--gag nested qPCR, based on the Alu-gag qPCR for HIV. Briefly, 50 ng of total DNA was used to perform a PCR using a forward primer that targeted genomic LINE 1 sequences located randomly near integrated proviruses and an MLV-specific gag reverse primer (Table 1). The PCR product was diluted 10-fold, and 2.4 µl was used as input for the second qPCR, which was performed using MLV long terminal repeat (LTR) primers (Table 1) [20]. The infection percentage was determined by analyzing the integrated copy numbers relative to the number of initially seeded cells.

#### Nucleic acid pulldowns

NIH3T3 and BMDC cells were infected with MLV (MOI = 1) in the presence of 2 µg/ml Polybrene (Sigma-Aldrich), and cells were incubated on ice for 1 h to allow virus binding. Cells were washed in cold phosphate-buffered saline and incubated at 37°C for 4 h. At 4 hpi the cells were fractionated by REAP method [47]. Each fraction was incubated overnight with anti-DNA-RNA Hybrid, clone S9.6 Ab (Sigma-Aldrich) and Protein A/G PLUS-agarose (Santa Cruz). The agarose was washed with high-salt buffer (25mM Tris-HCl, pH 7.8, 500mM NaCl, 1mM EDTA, 0.1% SDS, 1% TritonX-100, 10% glycerol) and LiCl buffer (25mM Tris-HCl, pH 7.8, 250mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate, 1mM EDTA, 10% glycerol). The immunoprecipitated nucleic acid was eluted from the agarose at 37°C in 100mM Tris-HCl, pH 7.8, 10mM EDTA, 1% SDS for 15 min. The eluted nucleic acid was purified using the DNeasy Kit (Qiagen) and analyzed by qPCR with strong-stop primers (primers P<sub>R</sub> and P<sub>U5</sub>) or by RT-qPCR with the P<sub>R</sub> primer and a primer that anneals to nucleotides 39 to 57 in tRNAPro (P<sub>tRNA</sub>) (13). A portion of each initial fraction was reserved and subjected to the same PCR analyses. For the nuclease treatments, the nucleic acids were treated at 37°C with 50 U RNase

A (Thermo) for 20 min in the presence of 300 mM NaCl, 4 U DNase I (Roche) with the reaction buffer provided with the enzyme for 20 min, or 3 U of RNase H (Thermo) for 20 min in the reaction buffer provided with the enzyme. Samples were purified using the DNeasy Kit (Qiagen) and the nucleic acids were subjected to qPCR or RT-qPCR analysis as described above, using a standard curve to estimate copy number. Data are presented as the ratio of immunoprecipitated nucleic acid to the total amount of the nucleic acid present in the extracts.

#### **Proximity ligation assays**

NIH3T3 or BMDC cells were seeded on glass coverslips in 24-well plates, infected with MLV (MOI = 1) for 4 hr, fixed with 4% paraformaldehyde–PBS, and permeabilized with 0.25% Triton X-100–PBS. Blocking and staining were performed with Duolink in situ PLA probes and detection reagents (Sigma-Aldrich). Images were taken at 40X using the Z-stacking function on a Keyence BZ-X710 microscope and analyzed with the BZ-X analyzer. PLA dots were counted manually in a blind fashion. Images were scored for spot localization in the nucleus (pink spots in the nucleus), nuclear membrane (red spots at the nuclear edge), and cytoplasm. Positive cells with spots in nucleus, nuclear membrane, or cytoplasm were normalized to the number of cells in the pictures. The primary antibodies used were anti-DNA-RNA hybrid, clone S9.6 (Sigma-Aldrich), polyclonal goat anti-MLV NC antibody (NCI Repository), polyclonal goat anti-MLV RT antibody (NCI Repository), anti-MLV-p30 (rat monoclonal R187, ATCC-CRL1912), anti-NUP358 (sc-74518, Santa Cruz), and anti-NUP62 (610498, BD Biosciences).

#### RNAi knockdown

For the depletion of nucleoporins in NIH3T3s and BMDCs, siRNAs from Ambion were used (catalog no: 4390771; NUP358: s72722; Nup62: n424643; Nup88: s72105; Nup153: s104224; Nup214: s105773). BMDCs were transfected using the reverse-transfection method with Lipo-fectamine RNAi MAX reagent (Invitrogen). siRNA depletion was carried out for 48 h prior to infection with MLV. RNA was isolated using the RNeasy minikit (Qiagen). RT-qPCR was performed using the GoTaq 1-step RT-qPCR system (Promega). Knockdowns were verified using primers described in Table I, for each nucleoporin, and protein expression was measured by immunofluorescence microscopy.

#### Immunofluorescence microscopy

Primary antibodies used were mouse anti-NUP358 (sc-74518, Santa Cruz), mouse anti-NUP62 (610498, BD Biosciences), rabbit anti-NUP88 (AB231187, Abcam), rabbit anti-NUP153 (E316Z, Cell signaling), and rabbit anti-NUP214 (AB70497, Abcam). Goat antimouse IgG Alexa Fluor 488-conjugated (Invitrogen, A-11001) and goat anti-Rabbit IgG Alexa Flour 568-conjugated (Invitrogen, A-11011) secondary antibodies were used. Images were acquired using a Keyence BZ-X710 at 40X magnification. Data analysis was performed with BZ-X Analyzer software. The nucleoporin fluorescence analysis was calculated by averaging the total fluorescence intensity per total number of cells.

#### Statistical analysis and data deposition

Data represent the averages of at least 3 independent experiments or as otherwise indicated in the Figure legends. Statistical analysis was performed using GraphPad Prism 10.0.0 software.

Tests used to determine significance are indicated in the figure legends. Raw data for all figures are deposited as a Mendeley dataset at https://data.mendeley.com/datasets/zmgp7dsj3m/1.

## **Supporting information**

S1 Fig. Percentage of infected cells and sensitivity of S9.6 immunoprecipitates to RNaseH. A) and B) PCR to detect integrated MLV was normalized to cell number, assuming 1 integrant/cell: A) NIH3T3 cells; B) DCs. See Methods for details. C) Nuclear, cytoplasmic and total extracts from serum-starved NIH3T3 cells infected with MLV (MOI = 1) were immunoprecipitated with antibody S9.6, the nucleic acid was released from the immunoprecipitates, treated with the indicated enzymes and subjected to qPCR. Shown is the average of 3 experiments  $\pm$  SD.

(TIF)

**S2 Fig. Cell cycle analysis in arrested NIH3T3 cells.** Cell cycle analysis after aphidicolin or low serum treatment. To the right is shown the percentage of ZOMBIE-stained cells after each treatment. See Methods for details. (TIF)

**S3 Fig. PLA showing RT-S9 interaction in uninfected NIH3T3 cells.** PLA was performed using antibodies to MLV RT and S9.6. Arrows indicate PLA spots. See legend to Fig 2 for details.

(TIF)

**S4 Fig. RT or S9.6 antibodies alone give no PLA signal.** A) PLA with RT Ab alone in MLV-infected NIH3T3 cells. B) PLA with S9.6 Ab alone in MLV-infected NIH3T3 cells. See legend to Fig 2 for details. (TIF)

**S5 Fig. Infected DCs shed virus.** Supernatants from DCs was collected 48 hpi and subjected to RT-qPCR using primers to SU (A) or used for plaque assays on NIH3T3 cells (B). See Methods section for details.

(TIF)

S6 Fig. p12 mutant virus shows similar integration defects to DCs treated with raltegravir. Cells were pretreated with raltegravir prior to and during infection. At 24 hpi, nuclear DNA was amplified with primers that detect 2-LTR circles. Experiments were performed 3 times. Significance was determined by 2-way ANOVA. \* $P \le 0.04$ ; \*\*\* $P \le 0.001$ . (TIF)

**S7 Fig. Knockdown of one NUP decreases expression of the other NUPs in BMDCs.** BMDCs were transfected with the indicated siRNAs and immunofluorescence with antibodies to the different NUPs was performed. Representative images are shown.

(TIF)

**S8 Fig. Purity of dendritic cells.** Cells were stained with anti-CD11c antibodies. Representative FACS histograms for different isolations are shown. (TIF)

**S9 Fig. Western blots of recombinant viruses.** Equal amounts of virus, as determined by viral RNA, were subjected to western blot analysis with anti-MLV antisera. (TIF)

#### Acknowledgments

We thank David Ryan for help with mouse breeding and Monica Roth for the MLV p12 mutant plasmid. AZT and raltegravir was obtained through the NIH AIDS Reagent Program,

## **Author Contributions**

Conceptualization: Karen Salas-Briceno, Wenming Zhao, Susan R. Ross.

Data curation: Karen Salas-Briceno, Wenming Zhao.

Formal analysis: Karen Salas-Briceno, Wenming Zhao, Susan R. Ross.

Funding acquisition: Susan R. Ross.

Investigation: Karen Salas-Briceno, Wenming Zhao, Susan R. Ross.

Methodology: Karen Salas-Briceno, Wenming Zhao.

Project administration: Susan R. Ross.

Supervision: Susan R. Ross.

Writing - original draft: Karen Salas-Briceno, Wenming Zhao, Susan R. Ross.

Writing - review & editing: Karen Salas-Briceno, Wenming Zhao, Susan R. Ross.

#### References

- Boeke JD, Stoye JP. Retrotransposons, endogenous retroviruses, and the evolution of retroelements. In: Coffin JM, Hughes SM, Varmus HE, editors. Retroviruses. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1997. p. 343–436.
- Hulme AE, Perez O, Hope TJ. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc Natl Acad Sci U S A. 2011; 108(24):9975–80. Epub 2011/06/02. https:// doi.org/10.1073/pnas.1014522108 [pii]10.1073/pnas.1014522108. PMID: 21628558; PubMed Central PMCID: PMC3116424.
- Poeschla EM. Integrase, LEDGF/p75 and HIV replication. Cell Mol Life Sci. 2008; 65(9):1403–24. Epub 2008/02/12. https://doi.org/10.1007/s00018-008-7540-5 PMID: 18264802.
- Sharma A, Larue RC, Plumb MR, Malani N, Male F, Slaughter A, et al. BET proteins promote efficient murine leukemia virus integration at transcription start sites. Proc Natl Acad Sci U S A. 2013; 110 (29):12036–41. https://doi.org/10.1073/pnas.1307157110 PMID: 23818621; PubMed Central PMCID: PMC3718171.
- Aiyer S, Swapna GV, Malani N, Aramini JM, Schneider WM, Plumb MR, et al. Altering murine leukemia virus integration through disruption of the integrase and BET protein family interaction. Nucleic Acids Res. 2014; 42(9):5917–28. Epub 20140312. https://doi.org/10.1093/nar/gku175 PMID: 24623816; PubMed Central PMCID: PMC4027182.
- Matreyek KA, Engelman A. Viral and cellular requirements for the nuclear entry of retroviral preintegration nucleoprotein complexes. Viruses. 2013; 5(10):2483–511. https://doi.org/10.3390/v5102483 PMID: 24103892; PubMed Central PMCID: PMC3814599.
- Roe T, Reynolds TC, Yu G, Brown PO. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 1993; 12(5):2099–108. https://doi.org/10.1002/j.1460-2075.1993.tb05858.x PMID: 8491198; PubMed Central PMCID: PMC413431.
- Harel J, Rassart E, Jolicoeur P. Cell cycle dependence of synthesis of unintegrated viral DNA in mouse cells newly infected with murine leukemia virus. Virol. 1981; 110:202–7. https://doi.org/10.1016/0042-6822(81)90022-2 PMID: 7210505
- Qu K, Glass B, Dolezal M, Schur FKM, Murciano B, Rein A, et al. Structure and architecture of immature and mature murine leukemia virus capsids. Proc Natl Acad Sci U S A. 2018; 115(50):E11751–E60. https://doi.org/10.1073/pnas.1811580115 PMID: 30478053; PubMed Central PMCID: PMC6294937.
- Zila V, Margiotta E, Turonova B, Muller TG, Zimmerli CE, Mattei S, et al. Cone-shaped HIV-1 capsids are transported through intact nuclear pores. Cell. 2021; 184(4):1032–46 e18. Epub 20210210. https:// doi.org/10.1016/j.cell.2021.01.025 PMID: 33571428; PubMed Central PMCID: PMC7895898.

- Wanaguru M, Barry DJ, Benton DJ, O'Reilly NJ, Bishop KN. Murine leukemia virus p12 tethers the capsid-containing pre-integration complex to chromatin by binding directly to host nucleosomes in mitosis. PLoS Pathog. 2018; 14(6):e1007117. https://doi.org/10.1371/journal.ppat.1007117 PMID: 29906285; PubMed Central PMCID: PMC6021111.
- Low A, Okeoma CM, Lovsin N, de las Heras M, Taylor TH, Peterlin BM, et al. Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology. 2009; 385(2):455–63. Epub 2009/01/20. https://doi.org/10.1016/j.virol.2008.11.051 PMID: 19150103; PubMed Central PMCID: PMC3124558.
- Stavrou S, Aguilera AN, Blouch K, Ross SR. DDX41 Recognizes RNA/DNA Retroviral Reverse Transcripts and Is Critical for In Vivo Control of Murine Leukemia Virus Infection. MBio. 2018; 9(3). https://doi.org/10.1128/mBio.00923-18 PMID: 29871919; PubMed Central PMCID: PMC5989071.
- Courreges MC, Burzyn D, Nepomnaschy I, Piazzon I, Ross SR. Critical role of dendritic cells in mouse mammary tumor virus in vivo infection. J Virol. 2007; 81:3769–77.
- Dharan A, Bachmann N, Talley S, Zwikelmaier V, Campbell EM. Nuclear pore blockade reveals that HIV-1 completes reverse transcription and uncoating in the nucleus. Nat Microbiol. 2020; 5(9):1088–95. https://doi.org/10.1038/s41564-020-0735-8 PMID: 32483230.
- Francis AC, Marin M, Singh PK, Achuthan V, Prellberg MJ, Palermino-Rowland K, et al. HIV-1 replication complexes accumulate in nuclear speckles and integrate into speckle-associated genomic domains. Nat Commun. 2020; 11(1):3505. https://doi.org/10.1038/s41467-020-17256-8 PMID: 32665593; PubMed Central PMCID: PMC7360574.
- Muller TG, Zila V, Peters K, Schifferdecker S, Stanic M, Lucic B, et al. HIV-1 uncoating by release of viral cDNA from capsid-like structures in the nucleus of infected cells. Elife. 2021; 10. <u>https://doi.org/10.7554/eLife.64776 PMID: 33904396</u>.
- Li C, Burdick RC, Nagashima K, Hu WS, Pathak VK. HIV-1 cores retain their integrity until minutes before uncoating in the nucleus. Proc Natl Acad Sci U S A. 2021; 118(10). <u>https://doi.org/10.1073/pnas.</u> 2019467118 PMID: 33649225; PubMed Central PMCID: PMC7958386.
- Christensen DE, Ganser-Pornillos BK, Johnson JS, Pornillos O, Sundquist WI. Reconstitution and visualization of HIV-1 capsid-dependent replication and integration in vitro. Science. 2020; 370(6513). https://doi.org/10.1126/science.abc8420 PMID: 33033190.
- Salas-Briceno K, Ross SR. Repair of APOBEC3G-Mutated Retroviral DNA In Vivo Is Facilitated by the Host Enzyme Uracil DNA Glycosylase 2. J Virol. 2021; 95(22):e0124421. Epub 20210901. https://doi. org/10.1128/JVI.01244-21 PMID: 34468176; PubMed Central PMCID: PMC8549519.
- Stavrou S, Nitta T, Kotla S, Ha D, Nagashima K, Rein AR, et al. Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex. Proc Natl Acad Sci U S A. 2013; 110(22):9078–83. Epub 2013/05/15. https://doi.org/10.1073/ pnas.1217399110 PMID: 23671100; PubMed Central PMCID: PMC3670389.
- Stavrou S, Blouch K, Kotla S, Bass A, Ross SR. Nucleic acid recognition orchestrates the anti-viral response to retroviruses. Cell Host Microbe. 2015; 17(4):478–88. https://doi.org/10.1016/j.chom.2015. 02.021 PMID: 25816774; PubMed Central PMCID: PMC4393365.
- Lahaye X, Satoh T, Gentili M, Cerboni S, Conrad C, Hurbain I, et al. The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells. Immunity. 2013; 39(6):1132–42. https://doi.org/10.1016/j.immuni.2013.11.002 PMID: 24269171.
- Kumar S, Morrison JH, Dingli D, Poeschla E. HIV-1 activation of innate immunity depends strongly on the intracellular level of TREX1 and sensing of incomplete reverse transcription products. J Virol. 2018. https://doi.org/10.1128/JVI.00001-18 PMID: 29769349.
- Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol. 2010; 11(11):1005–13. Epub 2010/09/28. https://doi.org/10.1038/ni.1941 [pii]10.1038/ni.1941. PMID: 20871604; PubMed Central PMCID: PMC2958248.
- Sumner RP, Harrison L, Touizer E, Peacock TP, Spencer M, Zuliani-Alvarez L, et al. Disrupting HIV-1 capsid formation causes cGAS sensing of viral DNA. EMBO J. 2020; 39(20):e103958. https://doi.org/ 10.15252/embj.2019103958 PMID: 32852081; PubMed Central PMCID: PMC7560218.
- Muller TG, Zila V, Muller B, Krausslich HG. Nuclear Capsid Uncoating and Reverse Transcription of HIV-1. Annu Rev Virol. 2022; 9(1):261–84. Epub 20220615. https://doi.org/10.1146/annurev-virology-020922-110929 PMID: 35704745.
- Liszewski MK, Yu JJ, O'Doherty U. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods. 2009; 47(4):254–60. Epub 20090203. https://doi.org/10.1016/j.ymeth.2009.01.002 PMID: 19195495; PubMed Central PMCID: PMC2862469.

- Mendoza R, Vaughan AE, Miller AD. The left half of the XMRV retrovirus is present in an endogenous retrovirus of NIH/3T3 Swiss mouse cells. J Virol. 2011; 85(17):9247–8. Epub 20110622. <u>https://doi.org/ 10.1128/JVI.05137-11 PMID: 21697491</u>; PubMed Central PMCID: PMC3165791.
- Tzavaras T, Eftaxia S, Tavoulari S, Hatzi P, Angelidis C. Factors influencing the expression of endogenous reverse transcriptases and viral-like 30 elements in mouse NIH3T3 cells. Int J Oncol. 2003; 23 (4):1237–43. PMID: 12964010.
- Martinelli SC, Goff SP. Rapid reversion of a deletion mutation in Moloney murine leukemia virus by recombination with a closely related endogenous provirus. Virology. 1990; 174(1):135–44. <u>https://doi.org/10.1016/0042-6822(90)90062-v PMID: 2294637</u>.
- Stavrou S, Zhao W, Blouch K, Ross SR. Deaminase-Dead Mouse APOBEC3 Is an In Vivo Retroviral Restriction Factor. J Virol. 2018; 92(11). https://doi.org/10.1128/JVI.00168-18 PMID: 29593034; PubMed Central PMCID: PMC5952145.
- Okeoma CM, Lovsin N, Peterlin BM, Ross SR. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature. 2007; 445(7130):927–30. Epub 2007/01/30. <u>https://doi.org/10.1038/nature05540</u> [pii]10.1038/nature05540. PMID: 17259974.
- Zhao W, Akkawi C, Mougel M, Ross SR. Murine leukemia virus P50 protein counteracts APOBEC3 by blocking its packaging. J Virol. 2020. https://doi.org/10.1128/JVI.00032-20 PMID: 32641479.
- Elis E, Ehrlich M, Prizan-Ravid A, Laham-Karam N, Bacharach E. p12 tethers the murine leukemia virus pre-integration complex to mitotic chromosomes. PLoS Pathog. 2012; 8(12):e1003103. Epub 20121227. https://doi.org/10.1371/journal.ppat.1003103 PMID: 23300449; PubMed Central PMCID: PMC3531515.
- Brzezinski JD, Modi A, Liu M, Roth MJ. Repression of the chromatin-tethering domain of Murine Leukemia Virus p12. J Virol. 2016; 90(24):11197–207. Epub 20161128. <u>https://doi.org/10.1128/JVI.01084-16</u> PMID: 27707926; PubMed Central PMCID: PMC5126376.
- Engelman AN. HIV Capsid and Integration Targeting. Viruses. 2021; 13(1). Epub 20210118. <u>https://doi.org/10.3390/v13010125</u> PMID: 33477441; PubMed Central PMCID: PMC7830116.
- Bhargava A, Lahaye X, Manel N. Let me in: Control of HIV nuclear entry at the nuclear envelope. Cytokine Growth Factor Rev. 2018; 40:59–67. Epub 20180227. https://doi.org/10.1016/j.cytogfr.2018.02. 006 PMID: 29526438.
- Francis AC, Marin M, Prellberg MJ, Palermino-Rowland K, Melikyan GB. HIV-1 uncoating and nuclear import precede the completion of reverse transcription in cell lines and in primary Macrophages. Viruses. 2020; 12(11). Epub 20201030. <u>https://doi.org/10.3390/v12111234</u> PMID: <u>33143125</u>; PubMed Central PMCID: PMC7693591.
- 40. Dharan A, Campbell EM. Teaching old dogmas new tricks: recent insights into the nuclear import of HIV-1. Curr Opin Virol. 2022; 53:101203. Epub 20220201. https://doi.org/10.1016/j.coviro.2022.101203 PMID: 35121335; PubMed Central PMCID: PMC9175559.
- Hulme AE, Kelley Z, Foley D, Hope TJ. Complementary assays reveal a low level of CA associated with viral complexes in the nuclei of HIV-1-infected cells. J Virol. 2015; 89(10):5350–61. <u>https://doi.org/10.1128/JVI.00476-15 PMID: 25741002</u>; PubMed Central PMCID: PMC4442523.
- Lin DH, Hoelz A. The structure of the nuclear pore complex (an update). Annu Rev Biochem. 2019; 88:725–83. Epub 20190318. https://doi.org/10.1146/annurev-biochem-062917-011901 PMID: 30883195; PubMed Central PMCID: PMC6588426.
- Le Sage V, Mouland AJ. Viral subversion of the nuclear pore complex. Viruses. 2013; 5(8):2019–42. Epub 20130816. https://doi.org/10.3390/v5082019 PMID: 23959328; PubMed Central PMCID: PMC3761240.
- 44. Haugh KA, Ladinsky MS, Ullah I, Stone HM, Pi R, Gilardet A, et al. In vivo imaging of retrovirus infection reveals a role for Siglec-1/CD169 in multiple routes of transmission. Elife. 2021; 10. Epub 20210705. https://doi.org/10.7554/eLife.64179 PMID: 34223819; PubMed Central PMCID: PMC8298093.
- 45. Liu XH, Xu W, Russ J, Eiden LE, Eiden MV. The host range of gammaretroviruses and gammaretroviral vectors includes post-mitotic neural cells. PLoS One. 2011; 6(3):e18072. Epub 20110328. <u>https://doi.org/10.1371/journal.pone.0018072</u> PMID: 21464894; PubMed Central PMCID: PMC3065480.
- 46. Gao D, Wu J, Wu YT, Du F, Aroh C, Yan N, et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science. 2013; 341(6148):903–6. https://doi.org/10.1126/science. 1240933 PMID: 23929945; PubMed Central PMCID: PMC3860819.
- Suzuki K, Bose P, Leong-Quong RY, Fujita DJ, Riabowol K. REAP: A two minute cell fractionation method. BMC research notes. 2010; 3:294. <u>https://doi.org/10.1186/1756-0500-3-294</u> PMID: 21067583; PubMed Central PMCID: PMC2993727.